After the publication of the revised edition, therapeutic drugs described in “Future Treatment”
were approved and important evidence for pharmacologic therapy and nonpharmacologic …

Variants in> 12 genes encoding sarcomeric proteins can cause various cardiomyopathies.
The two most common are hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy …

Background The selective cardiac myosin activator omecamtiv mecarbil has been shown to
improve cardiac function in patients with heart failure with a reduced ejection fraction. Its …

Heart Failure Society (JHFS). The working committee for this project includes members and
collaborators involved in the previous versions of the heart failure guidelines and members …

Heart failure is a pressing worldwide public-health problem with millions of patients having
worsening heart failure. Despite all the available therapies, the condition carries a very poor …

Hypertrophic cardiomyopathy (HCM) is an inherited disease of heart muscle that can be
caused by mutations in sarcomere proteins. Clinical diagnosis depends on an abnormal …

Heart failure is a global problem with an estimated prevalence of 38 million patients
worldwide, a number that is increasing with the ageing of the population. It is the most …

Myosin modulators are a novel class of pharmaceutical agents that are being developed to
treat patients with a range of cardiomyopathies. The therapeutic goal of these drugs is to …

Background Impaired contractility is a feature of heart failure with reduced ejection fraction.
We assessed the pharmacokinetics and effects on cardiac function and structure of the …

Medicine is an ever-changing science. As new research and clinical experience broaden
our knowledge, changes in treatment and drug therapy are required. The authors and the …